[Treatment of Parkinson's syndrome with L-dopa and L-carbidopa (author's transl)].
In a clinical investigation on the treatment of Parkinson's syndrome it is shown that a combination of L-dopa with decarboxylase inhibitor (L-carbidopa) shows advantages compared to treatment with L-dopa alone. To achieve the same therapeutic effect a quarter of the dose is sufficient; the good tolerance, even in relation to the digestive and cardiovascular apparatus, permits the use of relatively larger daily doses. The favorable action appears more quickly. The effect of the treatment can be potentiated by pyridoxine. The only disadvantage is the fairly frequent occurrence of hyperkinesia, especially of oral automatism. But treatment does not need to be broken off because of this.
D000328:Adult; D000368:Aged; D002230:Carbidopa / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D006948:Hyperkinesis / Q000139:chemically induced; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D011736:Pyridoxine / Q000627:therapeutic use
D004338:Drug Combinations; D006834:Hydrazines; D007980:Levodopa; D011736:Pyridoxine; D002230:Carbidopa
Behandlung des Parkinson-Syndroms mit L-Dopa und L-Carbidopa